Abstract
The design and evaluation of low molecular weight peptide-based severe acute respiratory syndrome (SARS) chymotrypsin-like protease (3CL) protease inhibitors are described. A substrate-based peptide aldehyde was selected as a starting compound, and optimum side-chain structures were determined, based on a comparison of inhibitory activities with Michael type inhibitors. For the efficient screening of peptide aldehydes containing a specific C-terminal residue, a new approach employing thioacetal to aldehyde conversion mediated by N-bromosuccinimide was devised. Structural optimization was carried out based on X-ray crystallographic analyses of the R188I SARS 3CL protease in a complex with each inhibitor to provide a tetrapeptide aldehyde with an IC 50 value of 98 nM. The resulting compound carried no substrate sequence, except for a P 3 site directed toward the outside of the protease. X-ray crystallography provided insights into the protein-ligand interactions.
Original language | English |
---|---|
Pages (from-to) | 7962-7973 |
Number of pages | 12 |
Journal | Journal of Medicinal Chemistry |
Volume | 54 |
Issue number | 23 |
DOIs | |
Publication status | Published - 2011 Dec 8 |